Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Activated HER3 as a marker for predicting therapeutic efficacy

Activated HER3 as a marker for predicting therapeutic efficacy

US Patent 10365283 · Granted Jul 30, 2019

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Tandem diabody for CD16A-directed NK-cell engagement2025
Bispecific EGFR/CD16 antigen-binding protein2024
Human anti-IFN-α antibodies2024
Multivalent FV antibodies2023
Combination of an anti-CD16A antibody with a cytokine2022
Bispecific EGFR/CD16 antigen-binding protein2022
Antibodies directed to HER-3 and uses thereof2022
Antibodies directed to HER-3 and uses thereof2022
Tandem diabody for CD16A-directed NK-cell engagement2021
Combination of a CD30XCD16 antibody with a PD-1 antagonist for therapy2021
NK cell engaging antibody fusion constructs2021
CDNA encoding a monoclonal anti-IL-32 antibody and methods for the production of2021